Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4576023
Max Phase: Preclinical
Molecular Formula: C23H11F6NO4S2
Molecular Weight: 543.47
Molecule Type: Unknown
Associated Items:
ID: ALA4576023
Max Phase: Preclinical
Molecular Formula: C23H11F6NO4S2
Molecular Weight: 543.47
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(c1ccc(-c2cc(F)c(F)c(NS(=O)(=O)c3ccc(F)cc3)c2)s1)c1cc(F)c(F)c(O)c1F
Standard InChI: InChI=1S/C23H11F6NO4S2/c24-11-1-3-12(4-2-11)36(33,34)30-16-8-10(7-14(25)20(16)28)17-5-6-18(35-17)22(31)13-9-15(26)21(29)23(32)19(13)27/h1-9,30,32H
Standard InChI Key: KAOIHZYOBKLKIX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 543.47 | Molecular Weight (Monoisotopic): 543.0034 | AlogP: 5.99 | #Rotatable Bonds: 6 |
Polar Surface Area: 83.47 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 6.17 | CX Basic pKa: | CX LogP: 6.03 | CX LogD: 4.82 |
Aromatic Rings: 4 | Heavy Atoms: 36 | QED Weighted: 0.18 | Np Likeness Score: -1.25 |
1. Abdelsamie AS, Salah M, Siebenbürger L, Merabet A, Scheuer C, Frotscher M, Müller ST, Zierau O, Vollmer G, Menger MD, Laschke MW, van Koppen CJ, Marchais-Oberwinkler S, Hartmann RW.. (2019) Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis., 62 (15): [PMID:31343176] [10.1021/acs.jmedchem.9b00932] |
Source(1):